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BACKGROUND: To systematically review and analyse the associations between fat and muscle mass measures with overall survival
in men with prostate cancer.
METHODS: A systematic search was conducted in CINAHL, Cochrane Library, EMBASE, PubMed, and Web of Science databases
from inception to December 2020, while abstracts from the American Society of Clinical Oncology (ASCO), Clinical Oncology Society
of Australia (COSA), and the American College of Sports Medicine (ACSM) conferences were searched from 2014 to 2020. Eligible
articles examined the association of body composition measures, such as fat mass (e.g., fat mass, visceral adipose tissue (VAT),
subcutaneous adipose tissue (SAT), and VAT/SAT) and muscle mass measures, with overall survival in prostate cancer patients at
any treatment stage. The primary endpoint was overall survival. Random-effect meta-analysis was conducted for studies reporting
multivariable or univariable analysis assessing the associations of fat mass measures (i.e., fat mass, VAT, SAT, VAT/SAT) and muscle
mass measures with overall survival.
RESULTS: Sixteen cohort studies that comprised 4807 men with prostate cancer were included. Total adiposity (hazard ratio (HR)
0.98, 95% CI: 0.75–1.28, p= 0.888) and VAT (HR 1.03, 95% CI: 0.74–1.43, p= 0.873) were not significantly associated with overall
survival, while higher subcutaneous adipose tissue levels were associated with higher survival (HR 0.68, 95% CI: 0.54–0.84, p=
0.001). Greater mortality risk was found in patients with localised (HR 1.91, 95% CI: 1.40–2.62, p < 0.001) and advanced disease (HR
1.43, 95% CI: 1.07–1.92, p= 0.020) presenting with low levels of muscle mass compared to those presenting with high levels.
DISCUSSION: These results indicate that although overall adiposity should be cautiously interpreted in regards to survival, high
muscle mass and SAT, and low VAT/SAT ratio values are associated with overall survival in men with prostate cancer.
Prostate Cancer and Prostatic Diseases; https://doi.org/10.1038/s41391-021-00442-0
INTRODUCTION
Prostate cancer is one of the most prevalent cancers worldwide,
accounting for one in five new cancer cases in men [1]. Among the
available treatments, androgen deprivation therapy (ADT) is
commonly used alone or in combination with other forms of
therapy to delay prostate cancer progression and improve survival
in patients with advanced prostate cancer [2]. However, as a result
of resistance to treatment [3, 4], altered metabolic profile and
body composition impairments such as increased fat mass and
reduced muscle mass [5, 6], patients are at an increased risk of
both cancer and non-cancer related mortality with 5-year survival
rates as low as 30% depending on health status and stage at the
time of prostate cancer diagnosis [7].
Obesity is a potential predictor of mortality in men with
prostate cancer [8, 9], affecting not only tumour biology [10] but
also the outcomes of radical prostatectomy and radiation therapy
[8, 11–13]. Significant associations between high body mass index
(BMI; >30 kgm−2) and a 23% increased risk for all-cause mortality
[9], or increases of 5 kgm−2 with a 20% increased risk of prostate
cancer-specific mortality [8] were reported in previous investiga-
tions. However, the association of obesity with all-cause mortality
is not consistent across all prostate cancer studies, with some
studies challenging this relationship by presenting no significant
association between higher BMI values and overall survival in this
population [14, 15], or presenting an inverse relationship between
obesity and survival [16]. This apparent obesity paradox may be
related to the reliance on BMI since this measure does not
differentiate lean from fat mass or visceral adipose tissue (VAT)
and subcutaneous adipose tissue (SAT) [17, 18], masking the
relationship of fat mass with overall survival in men with prostate
cancer [19, 20]. Furthermore, sarcopenia or the loss of muscle
mass has also been considered an important prognostic factor
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[6, 21–23], although its association with overall survival in men
with prostate cancer is largely controversial depending on the
cancer stage or phase of treatment [16, 24, 25]. Therefore, it
remains to be determined if excess fat mass, reduced levels of
muscle mass, or both treatment-related changes in body
composition have an impact on overall survival in men with
prostate cancer [20]. Determining these associations may poten-
tially inform specific and tailored strategies to improve overall
survival in this group of patients.
As a result, we investigated in this systematic review the role of
body composition on overall survival in men with prostate cancer,
analysing the associations of low muscle mass and high fat mass
as prognostic factors. In addition, a range of possible clinical (i.e.,
localised vs. advanced disease) and methodological (i.e., definition
of cut-off values for muscle mass, depots of fat mass and
controlling for BMI in multivariable analysis) variables that may
affect the associations of body composition with overall survival
were examined by subgroup analyses.
METHODS
Study selection procedure
A systematic search was conducted in the following electronic databases:
CINAHL, Cochrane Library, EMBASE, PubMed and Web of Science from
inception to December 2020. The search strategy is presented in the
Supplementary eAppendix 1. In addition, we also performed a manual
search of the reference lists provided in the selected papers as well as in
abstracts from the American Society of Clinical Oncology, Clinical Oncology
Society of Australia and the American College of Sports Medicine
conferences from 2014 to 2020. All procedures were undertaken in
accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement [26, 27] and based on the minimum criteria
established by the Cochrane Back Review Group [28], with registration at
the international prospective register of systematic reviews (PROSPERO
identifier: CRD42020218736).
This review included published articles and conference abstracts [29] of
studies evaluating the association of body composition measures, such as
fat mass (e.g., fat mass, VAT, SAT and VAT/SAT) and muscle mass measures,
with overall survival in prostate cancer patients at any treatment stage. The
primary and only outcome for this review was overall survival, defined as
the time in months of death by any cause. The exclusion criteria were: (1)
studies involving mixed cancer patients without specific information on
the results for prostate cancer patients; (2) studies not including or
reporting on the specific outcomes for this review, or did not include
sufficient information such as hazard ratios (HR) and 95% confidence
intervals (CI) for overall survival analysis; (3) studies evaluating specific
interventions for body composition such as nutrition or exercise; and (4)
written in a language other than English. In the search strategy, titles and
abstracts were first independently evaluated following the eligibility
criteria. When abstracts did not provide sufficient information, they were
selected for full-text evaluation. In addition, authors were contacted for
further information when necessary. Eligibility was assessed independently
in duplicate (PL and FS), with differences resolved by consensus.
Data extraction
Data extraction was performed via a standardised form. Clinical and
methodological information were extracted from the included studies such
as cancer stage and treatment, number of participants at baseline,
geographical region, age and BMI at baseline, fat and muscle mass
assessments (i.e., method of assessment, location and cut-off values),
follow-up period, HR for overall survival with their associated dispersion
values such as 95% CI or standard errors (SE) from univariable and
multivariable analyses, when available, and the number of covariates
included in the multivariable models.
Study quality assessment
The study quality assessment was evaluated according to the Newcastle-
Ottawa Quality Assessment Scale (NOS) for cohort studies [30]. The NOS
consists of eight items related to representativeness of the exposed cohort,
comparability based on the study design or analysis and assessment of
outcome and adequacy of follow-up with a total maximum score of 9 [30].
Studies were assessed by the following items: (1) Representativeness of the
exposed cohort; (2) Selection of the non-exposed cohort; (3) Ascertainment
of exposure; (4) Demonstration that outcome of interest was not present at
start of study; (5) Comparability of cohorts on the basis of the design or
analysis; (6) Assessment of outcome; (7) Was follow-up long enough for
outcomes to occur; (8) Adequacy of follow up of cohorts. The study quality
assessment for all included studies were performed independently by two
reviewers (PL and FS) with disagreements resolved by consensus.
Data analysis
Data from the associations of body composition with overall survival such
as HR and their associated dispersion values were pooled using inverse
variance random-effects models. These values were extracted from
univariable and multivariable models and log-transformed to be included
in further analyses. Analyses were conducted for studies reporting
multivariable or univariable analysis and subgroup analyses were provided
for the following: (1) removing outliers; (2) for prostate cancer subgroups
(stage or phase of treatment); (3) previously defined or median cut-off
values for muscle mass outcomes; (4) specific depots of fat and (5) studies
using BMI as a covariate or not in the multivariable models. A p value of
≤0.05 was considered statistically significant. Forest plots were generated
to present the results for multivariable and univariable analysis of fat and
muscle mass. Heterogeneity between studies was assessed by using the I2
statistic and the p value from χ2-based Cochran’s Q test with a high
heterogeneity defined by a threshold p value of 0.1 or I2 value greater than
50% [31]. We examined outliers using sensitivity analysis by omitting one
study at a time. To check for publication bias, contour-enhanced funnel
plots of log HR against its SE were generated and explored using Egger’s
regression asymmetry test when more than ten studies were available [32].
Analyses were conducted using the Review Manager (RevMan) software
from the Cochrane Collaboration (version 5.4, Copenhagen: The Nordic
Cochrane Centre) and the package ‘meta’ from R (R Core Team, 2020).
RESULTS
Studies included and characteristics
Of the 805 retrieved studies, 514 potential records were retained
for screening after duplicate removals. Of these, 373 were
excluded due to their irrelevance to the research question and
141 articles were deemed eligible and undertaken for review
(Fig. 1 and Supplementary eAppendix 2). A total of 16 cohort
studies undertaking retrospective analyses [16, 24, 25, 33–45] were
included in the primary analysis. During the eligibility assessment,
six additional studies [46–51] were initially selected and authors
contacted given the lack of specific information on the results for
prostate cancer patients. Responses were not obtained and, as a
result, these studies were not included in our review.
The characteristics of the individual studies are presented in
Tables 1 and 2. In summary, a total of 4807 prostate cancer
patients with a median age of 69.0 years (interquartile range (IQR):
67.2–71.3) and BMI of 26.6 kgm−2 (IQR: 24.3–28.7) participated in
the included studies. All studies except one derived fat and muscle
mass measures from CT scans [16, 24, 25, 34–45]. Most studies (n
= 11) included advanced prostate cancer patients (e.g., metastatic,
castration-resistant or metastatic castration-resistant patients)
[16, 24, 34, 35, 38, 39, 41–45], and the majority of patients
received treatments such as radiotherapy [33, 36–43] and ADT
[33, 35–37, 40–44] (n= 9 for both), followed by surgery
[25, 33, 36, 37, 39, 42, 43] and chemotherapy [34, 35, 39,
41–43, 45] (n= 7 for both), and novel hormonal agents such as
abiraterone and enzalutamide (n= 1) [24]. Regarding the quality
assessment, the median overall score was seven out of nine
ranging from 4 to 9 pts. The quality assessment of individual
studies is presented in eTable 1 (Supplementary material).
Fat mass and overall survival
Eight studies [24, 33–35, 40, 43–45] comparing high vs. low levels
of fat mass on overall survival were included in the analysis, with
six studies examining VAT (cut-off values reported: 52.2 cm2m−2
[23], 58.7 cm2m−2 [35], 59.4 cm2m−2 [43], 68.0 cm2m−2 [45],
100.0 cm2 [44] and 287.3 cm2 [40]) [24, 35, 40, 43–45], five studies
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examining SAT (cut-off values reported: 48.2 cm2m−2 [43],
51.7 cm2m−2 [24], 55.3 cm2m−2 [35], 64.1 cm2m−2 [45] and
36.4 cm2 [40]) [24, 35, 40, 43, 45], three studies examining VAT/
SAT ratio (with one study reporting a cut-off of 1.0 [44]) [34, 44, 45]
and one study examining whole-body fat mass [33]. Given that six
studies [24, 34, 35, 40, 43, 45] undertook multivariable models
controlling for BMI (median number of covariates of 7.0, ranging
from 2 to 12; with two studies also controlling for muscle mass
measures [24, 43]), the results from the meta-analysis provided no
differences in overall survival (HR 0.98, p= 0.888; Table 3) in a
sample of 1697 prostate cancer patients. The heterogeneity was
I2= 70%. Patients presenting with high levels of SAT are at an
advantage for overall survival compared to those presenting with
low SAT levels (HR 0.68, 95% CI: 0.54–0.84; Fig. 2A), while analysis
for VAT/SAT ratio provided a 50% greater mortality risk (HR 1.50,
95% CI: 1.15–1.97; Fig. 2A) to patients presenting high levels
compared to those presenting with low levels. No difference was
observed regarding VAT (p= 0.873; Fig. 2A), between results
derived VAT and VAT/SAT (χ2= 3.1; p= 0.080), while VAT and SAT
(χ2= 4.0; p= 0.045) and SAT and VAT/SAT (χ2= 19.5; p < 0.001)
were significantly different (Table 3). Differences were also not
observed between patients with localised and advanced disease
(χ2= 1.2; p= 0.275) or for studies controlling for BMI (χ2= 1.2; p=
0.273). In the univariable analysis, a 23% survival advantage was
found after removing the study of Stangl-Kremser et al. [45]
considered an outlier for the overall effect (HR 0.77, 95% CI:
0.64–0.92; Table 3), while the direction of the results was
maintained for all subgroup analyses (p= 0.061–0.438; Table 2
and Fig. 2B) without differences between covariates. No publica-
tion bias was found (p= 0.146; Supplementary eFig. 1A).
Muscle mass and overall survival
Thirteen studies [16, 24, 25, 33, 35–39, 41–43, 45] comparing low vs.
high levels of muscle mass on overall survival were included in the
analysis, with eight studies examining skeletal muscle mass index
(cut-off values reported: 43.0 or 53.0 cm2m−2 [16, 35, 41, 45],
45.0 cm2m−2 [24], 45.2 cm2m−2 [22], 49.9 cm2m−2 [43] and
55.0 cm2m−2 [37]) [16, 24, 35, 37, 41–43, 45], three studies
examining psoas muscle index (cut-off values reported:
4.7 cm2m−2 [25], 5.7 cm2m−2 [39] and 7.5 cm2m−2 [36])
[25, 36, 39], one study examining average psoas muscle size [38]
or skeletal muscle volume index (cut-off value reported: 28.7 kg [45]).
Meta-analysis involving data derived from multivariable models
(median number of covariates of 5, ranging from 1 to 12; with two
studies also controlling for fat mass measures [24, 43]) resulted in
50% greater mortality risk (HR 1.50, 95% CI: 1.11–2.05; Table 4 and
Fig. 2C) for patients presenting with low levels of muscle mass
compared to those presenting with high levels in a sample of 3275
men with prostate cancer. The study of Xu et al. [16] was considered
an outlier in the analysis. After adjustment, the meta-analysis
resulted in a HR of 1.63 (95% CI: 1.27–2.08; Table 3) with a
heterogeneity I2= 58%. The results were maintained in the
subgroup analyses (HR 1.43–1.91, p= <0.001–0.036) except for
studies controlling for BMI, which approached statistical significance
(HR 1.48, 95% CI: 0.98–2.26, p= 0.060). Similarly, results were similar
in univariable model analyses (HR 1.31–1.40; p= 0.002–0.004; Table 4
and Fig. 2D) except for those using previously defined cut-off values
(p= 0.271; Table 3). No differences were observed between
covariates in either multivariable or univariable models (p=
0.184–0.974). No publication bias was found (p= 0.301; Supplemen-
tary eFig. 1B).
Fig. 1 Flow chart. Flow chart of study selection process.
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DISCUSSION
In this review we examined the role of fat and muscle mass on
survival in men with prostate cancer. The main findings of our
study were: (1) although overall fat mass was not a prognostic
factor in men with prostate cancer, high levels of subcutaneous fat
and low levels of VAT/SAT were associated with a 32% and 50%
survival advantage, respectively, in patients at advanced stages of
the disease; and (2) patients presenting with low muscle mass
levels are at ~50% increased risk of mortality compared to those
presenting with high levels regardless of the cancer stage or
methodological characteristics. These results are clinically relevant
and indicate the importance of muscle mass in particular during
the course of therapy given the substantial impact on overall
survival of patients with prostate cancer.
Although obesity and the resulting metabolic environment are
deemed important factors for biochemical recurrence, metastatic
disease and mortality in men with prostate cancer [8, 9], our
finding is that total adiposity is not associated with overall survival
in prostate cancer patients. Interestingly, the reasons for this
particular outcome may be related to the metabolic differences
between SAT and VAT [52], with subcutaneous and visceral depots
of fat exerting conflicting effects on overall survival in prostate
cancer patients. For example, researchers have suggested that
VAT is closely associated with inflammatory cytokines (e.g.,
interleukin-6 and tumour necrosis factor-alpha) which may
potentially affect the tumour microenvironment [10, 52], while
subcutaneous tissue-derived factors such as leptin may act in
contrast by increasing insulin sensitivity and lipid metabolism,
thereby, effectively improving survival [52–55]. Another potential
explanation for the different findings reported previously [8, 9]
and this study may be related to cancer cachexia [19]. This
phenomenon may mislead the association of obesity with cancer
progression or mortality given the unintentional weight loss that
can occur during cancer treatment or even before the cancer
detection (i.e., reverse causation) in obese cancer patients [19].
Thus, the assessment of BMI alone at the time of cancer may not
inform whether prostate cancer patients have been obese before
diagnostic, precluding us to specifically observe the influence of
obesity on cancer survival in prostate cancer patients. Finally, our
data on fat mass and overall survival were derived from studies
mostly with advanced prostate cancer patients (i.e., metastatic and
castration-resistant patients) and this may explain the difference
between our findings and a previous study indicating significant
associations between BMI and weight gain with prostate cancer
outcomes in nonmetastatic patients [9]. Our results are in line with
previous studies concerning the prognostic value of different
depots of fat mass in cancer patients [24, 52, 56] and may indicate
the necessity to cautiously interpret total adiposity in this group of
patients, as different levels of obesity and depots of fat are
influencing overall survival in opposite ways [57]. Therefore, the
utilisation of the VAT/SAT ratio may be a good strategy to avoid
such conflicting effects derived from different depots of fat. For
example, in a previous study [34] high levels of VAT/SAT ratio were
significantly associated with shorter survival in normal weight
prostate cancer patients, although this relationship was not
observed in overweight or obese patients. Consequently, more
research is required to elucidate the physiological value of VAT/
SAT ratio on overall survival. Moreover, although high levels of
VAT did not significantly increase the risk of mortality in our
analysis, previous studies have indicated the association with
radical prostatectomy and radiation therapy outcomes [40, 58]
increasing surgical and recurrence risks, respectively, as well as
increased risk of cardiovascular and metabolic disease [59]. Thus,
more studies are necessary to elucidate the indirect or direct role
of VAT on overall survival in men with prostate cancer.
Contrary to the results regarding total adiposity, a high level of
muscle mass was associated with improved overall survival in
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methodological characteristics. This may be related to the
numerous benefits of muscle mass on metabolic health such as
regulating and mobilising natural killer cells into the tumour, or
even altering other biomarkers associated with the tumour
biology [60, 61]. In addition, crosstalk between muscle and other
organs has also emerged as a potential mechanism by which the
musculoskeletal system supresses cancer growth and therefore
increases overall survival in men with prostate cancer [60, 61].
Moreover, the present findings on muscle mass are in accordance
with several other studies indicating a relationship between
sarcopenia and survival in cancer patients [21–23] suggesting the
importance of improving or maintaining muscle mass in this
population before and during treatment [62]. For example, several
trials have demonstrated the benefits of exercise, specifically
resistance-based exercise programmes (i.e., anabolic exercise)
increasing muscle mass during and following ADT [63–66], as well
as preserving muscle mass in high-grade patients [67]. Therefore,
the findings from our review are clinically meaningful indicating
that muscle mass is an important prognostic factor for men with
prostate cancer regardless of cancer stage. Also, accrual or
maintenance of muscle mass through prescribed and tailored
exercise, specifically resistance-based exercise, undertaken before,
during and following cancer treatment would be beneficial in this
population to effectively increase the chances of overall survival.
The strengths of the present study are: (1) a relatively large
number of studies (n= 16) with up to 4807 prostate cancer
patients included; (2) the assessment of both univariable and
multivariable models; and (3) subgroup analyses based on
different clinical and methodological characteristics. However,
there are also some limitations which are worthy of comment.
First, only cohort studies undertaking retrospective analyses were
included in our review and this precludes determining causality of
body composition changes such as increase in muscle mass and
reduction in fat mass on overall survival. Future prospective
analyses are necessary to improve current knowledge by
indicating if interventions targeting fat and muscle mass are able
to improve overall and disease-specific survival as well as
recurrence in men with prostate cancer. In addition, researchers
used different definitions for sarcopenia such as the skeletal
muscle index, psoas muscle or median values, while no definition
for adiposity measures was used, leading to high heterogeneity
within the models. Sarcopenia has become a topic of great
interest in oncology [68]; however, poorly understood given the
lack of reporting on assessment characteristics and definitions. For
example, although studies had reported the time of body
composition assessment [25, 33, 34, 36, 37, 40–43, 45], the high
heterogeneity and lack of standardisation could misclassify
prostate cancer patients with obesity or sarcopenia and, therefore,
mask the impact of these outcomes on overall survival. Future
research should better inform definitions (i.e., cut-off values and
rationale) and time of assessments, and information about clinical
factors associated with muscle mass accrual or maintenance in
this group of patients. This will improve the assessment of
sarcopenia as well as provide information about its interaction
with obesity on overall survival in this group of patients and assist
future systematic reviews and meta-analyses. Nonetheless, sub-
group analysis was undertaken based on previously defined
methods to identify sarcopenia vs. median values to minimise
such bias, with the results largely maintained, although the same
was not conducted for fat mass given the lack of previous
definitions. Finally, data concerning the association of fat mass and
muscle mass measures with prostate cancer-specific and cardio-
vascular mortality as well as specific information about deaths are
limited. Therefore, it is not possible to account for deaths directly
or indirectly related to prostate cancer treatment comorbidities
(e.g., metabolic syndrome, diabetes, cardiovascular disease).
As far as we are aware, the present systematic review and meta-
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Table 3. Overall and subgroup analyses of high fat mass vs. low fat mass on overall survival in prostate cancer patients.
Outcomes No. of comparisons Sample size Main effect Subgroup differences
HR (95% CI) I2 p value χ2 p value
Multivariable analysis
Overall effect 8 1,697 0.98 (0.75–1.28) 70% 0.888 – –
Overall effect without outlier – – – – – – –
Population subgroups
Advanced disease 7 1,296 1.05 (0.75–1.48) 75% 0.769 1.2 0.273
Localised disease 2 802 0.82 (0.63–1.08) 15% 0.166
Outcome subgroups
VAT 4 821 1.03 (0.74–1.43) 52% 0.873 4.0a 0.045
SAT 3 758 0.68 (0.54–0.84) 0% 0.001 3.1b 0.080
VAT/SAT ratio 2 519 1.50 (1.15–1.97) 0% 0.003 19.5c <0.001
Multivariate models controlling for BMI
Yes 7 1,296 1.05 (0.75–1.48) 75% 0.769 1.2 0.273
No 2 802 0.82 (0.63–1.08) 15% 0.166
Univariable analysis
Overall effect 12 744 0.84 (0.67–1.05) 60% 0.126 – –
Overall effect without outlier 11 744 0.77 (0.64–0.92) 39% 0.005 – –
Population subgroups
Advanced disease 11 691 0.85 (0.67–1.08) 63% 0.189 – –
Localised disease 1 53 0.66 (0.31–1.43) – –
Outcome subgroups
VAT 5 691 0.93 (0.67–1.30) 59% 0.678 3.5a 0.061
SAT 4 606 0.64 (0.52–0.79) 0% <0.001 0.6b 0.438
VAT/SAT ratio 2 271 1.32 (0.59–2.96) 42% 0.503 2.8c 0.092
FM 1 53 0.66 (0.31–1.43) – – – –




Fig. 2 Random-effects meta-analysis. Association of low and high levels of VAT, SAT and VAT/SAT ratio (A, B) and muscle mass (C, D) with
overall survival in men with prostate cancer. Analyses derived from multivariable and univariate models were presented in A, C and B, D,
respectively. Higher VAT/SAT ratio indicates poorer overall survival. Overall effects analyses conducted with inverse variance random-effects
meta-analysis. Squares represent study-specific estimates; diamonds represent pooled hazard ratios estimates of random-effects meta-
analysis. *Study-specific estimate based on median values derived from skeletal muscle mass index and skeletal muscle volume indexes; FM
fat mass, SAT subcutaneous adipose tissue, VAT visceral adipose tissue.
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muscle mass in men with prostate cancer. In summary, increased
levels of muscle mass and SAT and reduced VAT/SAT ratio rather
than overall adiposity are important prognostic factors in men
with prostate cancer, even when controlling for multiple
confounding factors. Furthermore, we provide rationale for future
prospective analyses investigating the impact of sarcopenia and
changes in muscle mass during cancer treatment on prostate
cancer outcomes, as well as the investigation of strategies such as
exercise and nutritional interventions to improve survival in this
population.
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